# Renal Efficacy and Safety of the Novel Oral Small-Molecule GLP-1RA HRS-7535 Evaluated in Participants With Chronic Kidney Disease

> **NCT07625774** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Shandong Suncadia Medicine Co., Ltd.** · enrollment: 3690 (estimated)

## Conditions studied

- Chronic Kidney Disease

## Interventions

- **DRUG:** HRS-7535
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07625774
- **Lead sponsor:** Shandong Suncadia Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2031-05
- **Final completion:** 2031-07
- **Target enrollment:** 3690 (ESTIMATED)
- **Last updated:** 2026-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07625774

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07625774, "Renal Efficacy and Safety of the Novel Oral Small-Molecule GLP-1RA HRS-7535 Evaluated in Participants With Chronic Kidney Disease". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07625774. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*